Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Disease area: Airway diseases, Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. de Miquel, A. Schrodter, B. Miletzki, M. Gurniak, R. Lamarca, J. Jansat (Barcelona, Spain; Neuss, Tubingen, Germany). Low systemic exposure to aclidinium bromide, a novel long-acting anticholinergic, after multiple doses. Eur Respir J 2008; 32: Suppl. 52, 3607

Member's Comments

No comment yet.

Related content which might interest you: Bronchodilator/bronchoprotective effects of aclidinium bromide, a novel long-acting anticholinergic: a phase I study Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007 Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Rapid plasma hydrolysis of aclidinium bromide, a novel long-acting anticholinergic drug Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008 Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study Source: Annual Congress 2007 - New drugs for COPD Year: 2007 The preclinical urinary and renal safety profile of aclidinium bromide, a novel long-acting anticholinergic drug Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008 Once-daily administration of aclidinium bromide, a novel, long-acting anticholinergic: a phase II, dose-finding study Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Aclidinium bromide, a novel long-acting anticholinergic drug, has a good preclinical cardiovascular safety profile Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008 Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006 Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009 The efficacy of long-acting anticholinergic agent, tiotropium bromide on dynamic hyperinflation in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006 Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD Source: Eur Respir J 2007; 30: Suppl. 51, 356s Year: 2007 Evaluation of bronchodilator response to single dose tiotropium bromide Source: Eur Respir J 2004; 24: Suppl. 48, 504s Year: 2004 Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2-adrenoreceptor agonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Safety and pharmacokinetics of aclidinium bromide, a novel, long-acting muscarinic antagonist, in renally impaired subjects Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study}, Source: Eur Respir J 2012; 40: 830-836 Year: 2012 The combination therapy with inhaled tiotropium bromide and transdermal tulobuterol in COPD improves the peripheral airway function Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Monitoring of nasal permeability during the treatmrnt of patients with overlap syndrome with combined broncholytic drug (ipratropium bromide + salbutamol) Source: Eur Respir J 2001; 18: Suppl. 33, 216s Year: 2001 Absolute bioavailability of inhaled aclidinium bromide and safety and tolerability of aclidinium bromide administered intravenously in healthy subjects Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010